Latest Vascular endothelial growth factor Stories
For patients with KRAS wild-type untreated colorectal cancer, adding cetuximab or bevacizumab to combination chemotherapy offers equivalent survival.
TARRYTOWN, N.Y., June 27, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc.
Common stock to begin trading under "CASI" on June 16, 2014 ROCKVILLE, Md., June 13, 2014 /PRNewswire/ -- EntreMed, Inc.
INDIANAPOLIS, June 11, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the Phase III REACH trial of CYRAMZA(TM) (ramucirumab) in patients with hepatocellular carcinoma,
TARRYTOWN, N.Y., June 11, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc.
VANCOUVER, June 9, 2014 /PRNewswire/ - iCo Therapeutics Inc.
-- REVEL Data Published in The Lancet, Presented at Annual ASCO Meeting -- CHICAGO, June 2, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced detailed results from REVEL,
Phase III data for lenvatinib to be presented at ASCO WOODCLIFF LAKE, N.J., May 31, 2014 /PRNewswire/ -- Eisai Inc.
ROCKVILLE, Md., May 19, 2014 /PRNewswire/ -- EntreMed, Inc.
ROCKVILLE, Md., May 15, 2014 /PRNewswire/ -- EntreMed, Inc.
- A volcanic mudflow.